18:37 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Glenmark's Ryaltris meets in Phase III for seasonal allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a Phase III trial in 1,180 patients with seasonal allergic rhinitis showing that twice-daily Ryaltris mometasone/olopatadine met the primary endpoint of improving average morning and evening patient-reported...
19:11 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Glenmark's Ryaltris meets in Phase III for perennial allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported top-line data showing that twice-daily Ryaltris mometasone/olopatadine (formerly GSP 301) met the primary safety endpoint and a secondary efficacy endpoint in a Phase III trial to treat perennial allergic...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Indacaterol/glycopyrronium bromide/mometasone fuorate: Phase III started

Vectura and Sosei said Novartis began a double-blind, international Phase III trial to compare 2 dose levels of inhaled QVM149 vs. 2 dose levels of Novartis’ inhaled indacaterol/mometasone furoate ( QMF149) or salmeterol xinafoate/fluticasone...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Dupilumab: Phase IIa data

Top-line data from a double-blind, international Phase IIa trial in 60 patients with moderate to severe chronic sinusitis with nasal polyps who did not respond to intranasal corticosteroids showed that once-weekly subcutaneous dupilumab met the...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.79 to $167.04 last week after EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a rolling...
23:55 , Jul 24, 2014 |  BC Extra  |  Financial News

Intersect raises $55 million in IPO

Intersect ENT Inc. (NASDAQ:XENT) was up $1.92 (17%) to $12.92 on its first day of trading Thursday after raising $55 million through the sale of 5 million shares at $11 in an IPO. The $11...
07:00 , May 5, 2014 |  BioCentury  |  Finance

Pulling off the AZ gambit

Pfizer Inc. (NYSE:PFE) still has room to maneuver if it is really intent on using its bid for AstraZeneca plc (LSE:AZN; NYSE:AZN) to relocate in the more tax-friendly U.K. The trick is to provide enough cash...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Dupilumab: Phase II started

Regeneron disclosed in its 3Q13 earnings that it began a double-blind, placebo-controlled, international Phase II trial evaluating once-weekly subcutaneous dupilumab in combination with intranasal mometasone furoate spray in about 56 patients with nasal polyposis and...
01:32 , Feb 26, 2013 |  BC Extra  |  Financial News

Intersect announces first close of $30M D round

Intersect ENT Inc. (Menlo Park, Calif.) raised an undisclosed amount in the first close of a planned $30 million series D round led by new investor Norwest Venture Partners. All of the company's existing investors...